The combination of Ganmaidazao and Shengmai-Yin decoction is applied as adjuvant therapy for Type II diabetes mellitus via activation of HSL, PPARα, and AMPK/PI3K/AKT, and inhibition of SREBP-1/FAS, influencing insulin sensitivity, and lipid biosynthesis (Li et al., 2019). The gene discussed is SREBF1; the disease is type 2 diabetes mellitus.